223Ra-dichloride SPECT and planar quantitative images for targeted alpha-emitting therapy of bone metastases.

被引：0
|
作者：
Benabdallah, Nadia [3 ]
Bernardini, Michela [1 ]
de Labriolle-Vaylet, Claire [2 ]
Franck, Didier [3 ]
Desbree, Aurelie [3 ]
机构：
[1] Hapital Europaen George Pompidou, Paris, France
[2] Hapital Trousseau, Paris, France
[3] IRSN, Fontenay Aux Roses, France
来源：
JOURNAL OF NUCLEAR MEDICINE | 2016年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
1019
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Role of Advanced Practitioner in the clinical setting of a multi-disciplinary clinic for alpha emitting 223Radium-dichloride therapy for bone metastases in castration-resistant prostate cancer
    Jessop, M.
    Staker, A.
    Day, K.
    Aplin, M.
    Ryan, N.
    Cripps, H.
    Hosur, A.
    Singh, N.
    Robinson, A.
    Dizdarevic, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S257 - S258
  • [42] Open-label phase II study evaluating the efficacy of concurrent administration of radium Ra 223 dichloride (Ra-223) and abiraterone acetate (AA) in men with castration-resistant prostate cancer (CRPC) patients with symptomatic bone metastases.
    Shore, Neal D.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [43] Prognostic Value of Discordance Between 68Ga-PSMA PET/CT and 99mTc-HDP SPECT/CT Bone Scintigraphy in Metastatic Prostate Cancer Patients Treated with 223Ra-Dichloride
    Plouznikoff, N.
    Artigas, C.
    Gil, T.
    Flamen, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S648 - S648
  • [44] Quantitative gamma camera imaging of 227Th and 223Ra with application in 227Th targeted alpha therapy
    Larsson, E.
    Brolin, G.
    Cleton, A.
    Ohlsson, T.
    Hindorf, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S178 - S179
  • [45] Alpha-emitting Radium-223: two years follow up from a randomized phase II study in patients with bone metastases from hormone refractory prostate cancer
    Nilsson, S.
    Franzen, L.
    Parker, C.
    Bolstad, B.
    Ramdahl, T.
    Thuresson, M.
    Bruland, O.
    EJC SUPPLEMENTS, 2009, 7 (02): : 412 - 412
  • [46] A randomized open-label phase 2a study evaluating the efficacy and safely of radium 223 dichloride (Ra-223) in combination with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC) and bone metastases.
    Petrylak, Daniel Peter
    Rosenberg, Julie A.
    Garosi, Vittorio Luigi
    Siegel, Jonathan
    Goldin, Jonathan
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [47] Open-label phase II study evaluating the efficacy of concurrent administration of radium Ra 223 dichloride and abiraterone acetate in men with castration-resistant prostate cancer patients with symptomatic bone metastases.
    Nordquist, Luke T.
    Shore, Neal D.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [48] Evaluation of 223Ra therapy on bone metastases of prostate cancer by 18F-fluoride PET/CT, 18F-FDG PET/CT and bone scintigraphy/SPECT
    Kato, Katsuhiko
    Odagawa, Tetsuro
    Fujita, Naotoshi
    Tsutsumi, Yoshinori
    Abe, Shinji
    Yamamoto, Seiichi
    Naganawa, Shinji
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [49] External Beam Radiation Therapy (EBRT) Use and Safety With Radium-223 Dichloride (Ra-223) in Patients With Castration-Resistant Prostate Cancer (CRPC) and Symptomatic Bone Metastases (mets) From the ALSYMPCA Trial
    Finkelstein, S. E.
    Michalski, J. M.
    O'Sullivan, J.
    Parker, C.
    Garcia-Vargas, J.
    Sartor, O.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : S201 - S201
  • [50] External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial
    Paganelli, G.
    Rossetti, C.
    Aglietta, M.
    Messina, C.
    Versari, A.
    Michalski, J. M.
    O'Sullivan, J. M.
    Parker, C.
    Garcia-Vargas, J. E.
    Sartor, A.
    Finkelstein, S. E.
    ANNALS OF ONCOLOGY, 2015, 26 : 62 - 62
12345